Chi-Med Announces Surufatinib Granted US FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors

Hutchison China MediTech Limited announced that the FDA has granted two Fast Track Designations for the development of surufatinib, for the treatment of both advanced and progressive pancreatic neuroendocrine tumors (NET) and extra-pancreatic NET in patients who are not amenable for surgery.